DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA611641
Title:
Novel In Vitro/Ex Vivo Animal Modeling for Filovirus Aerosol Infection
Descriptive Note:
Annual rept. 15 Aug 2013-14 Aug 2014
Corporate Author:
SANOFI PASTEUR VAXDESIGN CORP ORLANDO FL
Report Date:
2014-09-01
Pagination or Media Count:
64.0
Abstract:
The Novel in vitro ex vivo animal modeling for filovirus aerosol infection program is a collaborative research effort between the USAMRIID Labs and Sanofi Pasteur VaxDesign to develop in vitro and ex vivo viral disease model systems composed of primary human and non-human primate cell lines, from species prone to filovirus infections. This work is relevant to the US Military due to the potential threat of biological bioterrorism in the military and civilian populations. To this end, Sanofi Pasteur VaxDesign is developing in vitro modular systems to dissect immunophysiological response to respiratory antigen of chemical and biological origin. This report summarizes the recent directions at the VaxDesign Sanofi Pasteur Campus related to quantitative methods to characterize barrier function, mode of antigen delivery, and related biological response to respiratory antigen. The in vitro mucosal tissue sensitivity was correlated with cellular composition, tissue confluence and chemical or biological agent entry pathways. The primary cell or cell line specific barrier function and related intrinsic tissue properties will be critical in the proposed in vitro VitroCell Cloud system. The mucosal tissue equivalent MTE module of the Modular Immune In Vitro Construct MIMIC system were exposed to aerosolized phase antigen delivery including live attenuated and inactivated influenza vaccine. Similarly, the MTE product has been successfully infected with two strains of Ebola and Zaire by our USAMRIID collaborators. The methods relating to the cloud phase application of influenza antigen will be applied to filovirus infection model at USAMRIID labs.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
